Neovacs S.A.

Neovacs SA is a France-based company active in the biotechnology industry. It specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The Company researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The Company focuses its development effort on two Kinoids for Crohn's disease, Rheumatoid Arthritis and lupus disease. Neovacs SA's portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The Company operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.
  • TickerA1CVKR
  • ISINFR0004032746
  • ExchangeFrankfurt Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance


ResearchPool Subscriptions

Get the most out of your insights

Get in touch